Division of Thoracic and Cardiovascular Surgery, University of Louisville, Louisville, Kentucky, USA.
Semin Thorac Cardiovasc Surg. 2011 Autumn;23(3):245-7. doi: 10.1053/j.semtcvs.2011.07.008.
Left ventricular assist devices (LVADs) are the treatment of choice for advanced heart failure that is refractory to medical therapy for both Bridge to Transplantation and Destination Therapy in appropriately selected patients. The newer continuous flow LVADs are more reliable and durable and have resulted in significant size reduction compared to pulsatile flow LVADs. This "miniaturization" of the LVAD has potential advantages including less surgical trauma for implantation. The HeartWare HVAD is a new continuous flow LVAD, currently in trials, that is designed to be implanted and contained completely within the pericardial space.
左心室辅助装置(LVAD)是治疗对药物治疗无效的晚期心力衰竭的首选方法,对于桥接移植和目的地治疗,在适当选择的患者中均适用。较新型的连续流 LVAD 更可靠、更耐用,与搏动流 LVAD 相比,体积显著缩小。这种 LVAD 的“小型化”具有潜在优势,包括植入手术创伤更小。HeartWare HVAD 是一种新型的连续流 LVAD,目前正在临床试验中,旨在完全植入并包含在心包腔内。